KINIKSA PHARMACEUTICALS
Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with a significant unmet medical need. It has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. It has three clinical-stage product candidates, one of which is anticipated to commence a Phase 3 clinical tr... ial in 2018. They follow a disciplined and methodical approach to selectively identify and acquire product candidates with strong biologic rationales or validated mechanisms of action. The company's portfolio of product candidates offers multiple development opportunities. By modulating different parts of the innate and adaptive immune system, these product candidates together have the potential to provide a variety of mechanisms to address multiple devastating diseases.
KINIKSA PHARMACEUTICALS
Industry:
Biopharma Biotechnology Medical
Founded:
2015-01-01
Address:
Hamilton, Hamilton, Bermuda
Country:
Bermuda
Website Url:
http://www.kiniksa.com
Total Employee:
11+
Status:
Active
Contact:
(781) 431-9100
Email Addresses:
[email protected]
Total Funding:
400 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager Content Delivery Network Domain Not Resolving Nginx Euro Microsoft Exchange Online
Similar Organizations
Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
AxisPharm
AxisPharm specializes in ADC drug development, bioconjugation, mass spectrometry, and structure elucidation.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Stock Details
Investors List
Fidelity
Fidelity investment in Series C - Kiniksa Pharmaceuticals
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Kiniksa Pharmaceuticals
Sofinnova Investments
Sofinnova Investments investment in Series C - Kiniksa Pharmaceuticals
Deerfield
Deerfield investment in Series C - Kiniksa Pharmaceuticals
Baker Brothers Advisors LLC
Baker Brothers Advisors LLC investment in Series C - Kiniksa Pharmaceuticals
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series C - Kiniksa Pharmaceuticals
ArrowMark Partners
ArrowMark Partners investment in Series C - Kiniksa Pharmaceuticals
Baker Brothers Advisors LLC
Baker Brothers Advisors LLC investment in Series B - Kiniksa Pharmaceuticals
Baker Brothers Advisors LLC
Baker Brothers Advisors LLC investment in Series A - Kiniksa Pharmaceuticals
Official Site Inspections
http://www.kiniksa.com
- Host name: 151.101.1.193
- IP address: 151.101.1.193
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Kiniksa Pharmaceuticals"
About Us | Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals (UK), Ltd. Third Floor 23 Old Bond Street London, UK W1S 4PZ; USA Headquarters Kiniksa Pharmaceuticals Corp. 100 …See details»
Our Leaders | Kiniksa Pharmaceuticals
Mei joined Kiniksa in 2018 and was promoted to VP of CMC in 2020 and to Group VP of Technical Operations in 2021. Before joining Kiniksa, Mei was the head of biologics …See details»
Kiniksa Pharmaceuticals - LinkedIn
Kiniksa offers competitive benefits and dynamic career opportunities across our organization. We foster a culture of passion, innovation, and rapid execution to help fulfill our mission ...See details»
Sanj K. Patel - CEO & Chairman at Kiniksa …
Sanj K. Patel is the CEO and Chairman of the Board of Kiniksa Pharmaceuticals, which is focused on developing and commercializing therapies for patients with devastating diseases and unmet medical need. ... Sanj is the founder and …See details»
Kiniksa Pharmaceuticals - Crunchbase Company Profile & Funding
Kiniksa Pharmaceuticals reported a 13% return for the week, contributing to a 60% gain for shareholders over three years. The company also beat revenue expectations for both the first …See details»
Kiniksa Pharmaceuticals Provides Corporate Update
Jan 4, 2024 Kiniksa increased the size of its salesforce to approximately 85 representatives by the end of 2023 to help drive further physician adoption and patient enrollments in 2024. …See details»
Kiniksa Pharmaceuticals | KNSA Stock Price, Company Overview
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from …See details»
Corporate Presentation - Kiniksa Pharmaceuticals
Kiniksa is eligible to receive up to approximately $600 million in certain clinical, regulatory, and sales-based milestones, before fulfilling upstream financial obligations Kiniksa is also eligible …See details»
Kiniksa Pharmaceuticals - Contacts, Employees, Board Members, …
Kiniksa Pharmaceuticals is developing therapies for inflammatory and autoimmune conditions.See details»
Kiniksa Pharmaceuticals - Funding, Financials, Valuation & Investors
Kiniksa Pharmaceuticals is registered under the ticker NASDAQ:KNSA . Their stock opened with $18.00 in its May 23, 2018 IPO. Stock Symbol NASDAQ:KNSA ; Money Raised at IPO …See details»
Events and Presentations | Kiniksa Pharmaceuticals
Sep 4, 2024 Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA 02421 USA (781) 431-9100; Switzerland Kiniksa Pharmaceuticals, GmbH Grafenaustrasse 5 6302 Zug, …See details»
Kiniksa Pharmaceuticals - Craft
Oct 29, 2024 Kiniksa Pharmaceuticals focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with …See details»
Patient Support and Treatment Access - Kiniksa
Physicians who receive a Kiniksa investigational or un-licensed product through a Managed Access program will be required to comply with all applicable laws, regulations, and …See details»
Kiniksa Pharmaceuticals Provides Corporate Update - Yahoo Finance
Jan 4, 2024 In fact, at the end of 2023 Kiniksa penetrated approximately 9% into the multiple-recurrence population, compared to approximately 5% at the end of 2022,” said Sanj K. Patel, …See details»
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year …
Feb 22, 2022 Kiniksa ended 2021 with $182.2 million of cash, cash equivalents and short-term investments and no debt. Financial Guidance . Kiniksa expects ARCALYST net revenue for …See details»
Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story
Oct 7, 2024 Kiniksa Pharmaceuticals ended the first half of 2024 with nearly $220 million worth of cash and marketable securities on its balance, after a net loss of $3.9 million for Q2. Net …See details»
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI ...
4 days ago LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a …See details»
Kiniksa Pharmaceuticals International, plc (KNSA) - Yahoo Finance
Find the latest Kiniksa Pharmaceuticals International, plc (KNSA) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year …
Feb 28, 2024 – ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product revenue …See details»